AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

FDA

FDA Approves Humira Biosimilar That Won’t Be Available Until 2023

The U.S. Food and Drug Administration (FDA) gave the green light to Hyrimoz, a biosimilar to AbbVie’s blockbuster drug Humira, five years ahead of the time it can be launched in U.S. markets.

November 1, 2018

2 min read

Alex Keown

Top 12 Life Science Companies Hiring Now

Fall is in full swing, but not falling short of jobs. Check out the top companies who are looking for candidates like you right now!

October 31, 2018

1 min read

Editorial Staff

Business

Galapagos and AbbVie restructure CF collaboration

Galapagos NV announce a restructuring of their cystic fibrosis (CF) alliance; AbbVie takes over all programs in CF and continues the development of a triple combination therapy for CF.

October 30, 2018

5 min read

Deals

AbbVie Takes Over Galapagos Cystic Fibrosis Collaboration Instead of Walking Away

What is AbbVie thinking? That’s the question of many investors, analysts and industry watchers as the Chicago-based AbbVie decided to buy up researcher partner Galapagos’ cystic fibrosis portfolio instead of walking away.

October 25, 2018

3 min read

Mark Terry

Business

Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week

Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.

October 24, 2018

5 min read

Mark Terry

Drug Development

Eli Lilly Updates Spondyloarthritis Trial Data and Long-Term Rheumatoid Arthritis Studies

Eli Lilly and Company presented positive data from two Phase III clinical trials at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting in Chicago yesterday.

October 23, 2018

3 min read

Mark Terry

Job Trends

BioSpace Movers and Shakers - Oct. 22

Execs at Novo Nordisk, AbbVie, and more made moves this week. Here’s a roundup of those changes.

October 19, 2018

4 min read

Alex Keown

Business

AbbVie Invests $100 Million in Morphic Therapeutics to Develop Integrin Inhibitors for Fibrotic Diseases

Weeks after Waltham, Mass.-based Morphic Therapeutic secured $80 million in Series B financing that was supported in part by AbbVie Ventures, the company struck a deal with the pharma giant to collaborate on the development of therapies for fibrosis-related indications.

October 18, 2018

2 min read

Alex Keown

Business

The Perils and Promise of Partnerships Between Biopharma and Data Companies

Recently, 23andMe partnered with GlaxoSmithKline, causing the Forbes Technology Council to cite eight ways these types of partnerships will affect disease treatments. These types of partnerships aren’t exactly new.

October 16, 2018

4 min read

Mark Terry

JOBS